Cargando…

Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study

OBJECTIVES: To better understand the real-world impact of biologic therapy in persons with Crohn’s disease (CD) and ulcerative colitis (UC), we evaluated the effect of marketplace introduction of infliximab on the population rates of hospitalisations and surgeries and public payer drug costs. DESIGN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murthy, Sanjay K, Begum, Jahanara, Benchimol, Eric I, Bernstein, Charles N, Kaplan, Gilaad G, McCurdy, Jeffrey D, Singh, Harminder, Targownik, Laura, Taljaard, Monica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Inflammatory Bowel Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6984056/ https://www.ncbi.nlm.nih.gov/pubmed/31196874 http://dx.doi.org/10.1136/gutjnl-2019-318440

Ejemplares similares

Trends in Epidemiology of Pediatric Inflammatory Bowel Disease in Canada: Distributed Network Analysis of Multiple Population-Based Provincial Health Administrative Databases
por: Benchimol, Eric I, et al.
Publicado: (2017)

Surgical Rates for Crohn’s Disease are Decreasing: A Population-Based Time Trend Analysis and Validation Study
por: Ma, Christopher, et al.
Publicado: (2017)

Rural and Urban Residence During Early Life is Associated with Risk of Inflammatory Bowel Disease: A Population-Based Inception and Birth Cohort Study
por: Benchimol, Eric I, et al.
Publicado: (2017)

The Inflammatory Bowel Diseases and Ambient Air Pollution: A Novel Association
por: Kaplan, Gilaad G, et al.
Publicado: (2010)

Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study
por: Clooney, Adam G, et al.
Publicado: (2021)

Outcome of tacrolimus and vedolizumab after corticosteroid and anti-TNF failure in paediatric severe colitis
por: Hamel, Blaise, et al.
Publicado: (2018)

Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling
por: Koelink, Pim J, et al.
Publicado: (2020)

Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: the VERNE study
por: Marin-Jimenez, Ignacio, et al.
Publicado: (2020)

Cell-centred meta-analysis reveals baseline predictors of anti-TNFα non-response in biopsy and blood of patients with IBD
por: Gaujoux, Renaud, et al.
Publicado: (2019)

Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease
por: Schmitt, Heike, et al.
Publicado: (2019)

Relapse after withdrawal from anti‐TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta‐analysis
por: Kennedy, N. A., et al.
Publicado: (2016)

TNFα inhibitors exacerbate Mycobacterium paratuberculosis infection in tissue culture: a rationale for poor response of patients with Crohn’s disease to current approved therapy
por: Qasem, Ahmad, et al.
Publicado: (2018)

Genetic polymorphisms in tumour necrosis factor receptors (TNFRSF1A/1B) illustrate differential treatment response to TNFα inhibitors in patients with Crohn’s disease
por: Qasem, Ahmad, et al.
Publicado: (2019)

Environmental risk factors for inflammatory bowel disease
por: Singh, Noreen, et al.
Publicado: (2022)

Antibiotic use differentially affects the risk of anti-drug antibody formation during anti-TNFα therapy in inflammatory bowel disease patients: a report from the epi-IIRN
por: Gorelik, Yuri, et al.
Publicado: (2022)

Proteomic analysis of ascending colon biopsies from a paediatric inflammatory bowel disease inception cohort identifies protein biomarkers that differentiate Crohn's disease from UC
por: Starr, Amanda E, et al.
Publicado: (2017)

Hospitalization With Clostridioides difficile in Pediatric Inflammatory Bowel Disease: a Population-Based Study
por: Kuenzig, M. Ellen, et al.
Publicado: (2022)

Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta‐analysis
por: Magro, Fernando, et al.
Publicado: (2023)

Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis
por: Kamm, M A, et al.
Publicado: (2008)

Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse
por: Arrieta, M C, et al.
Publicado: (2008)

Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition
por: Binion, D G, et al.
Publicado: (2008)

SHIP deficiency causes Crohn's disease-like ileitis
por: Kerr, William G, et al.
Publicado: (2010)

Treatment of Relapsing Mild-to-Moderate Ulcerative Colitis With the Probiotic VSL#3 as Adjunctive to a Standard Pharmaceutical Treatment: A Double-Blind, Randomized, Placebo-Controlled Study
por: Tursi, Antonio, et al.
Publicado: (2010)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Neuronal guidance molecule netrin-1 attenuates inflammatory cell trafficking during acute experimental colitis
por: Aherne, Carol M, et al.
Publicado: (2011)

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
por: Travis, Simon P L, et al.
Publicado: (2011)

Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel Disease
por: Cayatte, Corinne, et al.
Publicado: (2012)

Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2011)

Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial
por: Kruis, W, et al.
Publicado: (2009)

Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2011)

Abnormally expressed ER stress response chaperone Gp96 in CD favours adherent-invasive Escherichia coli invasion
por: Rolhion, Nathalie, et al.
Publicado: (2010)

Translocation of Crohn's disease Escherichia coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers
por: Roberts, Carol L, et al.
Publicado: (2010)

Serious Infection and Mortality in Patients With Crohn's Disease: More Than 5 Years of Follow-Up in the TREAT™ Registry
por: Lichtenstein, Gary R, et al.
Publicado: (2012)

Increased Epithelial Gaps in the Small Intestine Are Predictive of Hospitalization and Surgery in Patients With Inflammatory Bowel Disease
por: Turcotte, Jean-Francois, et al.
Publicado: (2012)

A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease
por: Lichtenstein, Gary R, et al.
Publicado: (2012)

Factors affecting outcomes in Crohn's disease over 15 years
por: Cosnes, Jacques, et al.
Publicado: (2012)

Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease
por: Kiesslich, R, et al.
Publicado: (2011)

Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability
por: Cani, P D, et al.
Publicado: (2009)

Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
por: Hébuterne, Xavier, et al.
Publicado: (2013)

Therapeutic Effect of Vitamin D Supplementation in a Pilot Study of Crohn's Patients
por: Yang, Linlin, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_h7ggnltcso54h57u0u2l53cj57